EML4-ALK融合基因与非小细胞肺癌

EML4-ALK fusion gene and non-small cell lung cancer

棘皮动物微管结合蛋白4（echinoderm microtubule associated protein-like4，EML4）与间变淋巴瘤激酶（anaplastic lymphoma kinase，ALK）形成的融合基因，被认为是非小细胞肺癌（NSCLC）新的分子靶点。EML4-ALK融合基因的发生率为3％～11％，该融合基因在年轻、腺癌、不吸烟或轻度吸烟的NSCLC患者中发生率较高，表达阳性者可以受益于ALK抑制剂（如克唑替尼）的治疗。本文重点阐述NSCLC中EML4-ALK融合基因的生物学特性、检测方法、临床特征和治疗方式。

The fusion gene of echinoderm microtubule-associated protein-like 4 （EML4） and anaplastie lymphoma kinase（ALK） has recently been identified as a new molecular target for non-small cell lung cancer （NSCLC）. EML4-ALK fusion gene is about 30%- 11% in patients with NSCLC, and it has a higher morbidity in NSCLC patients who are young, without or with light smoking history and with ad EML4-ALK positive NSCLC patients may be treated with ALK inhibitor （crizotinib）. This review focuses on the biology, detection method, clinical characteristics and the therapeutic application of EML4-ALK in NSCLC.